NCT03698331 - The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

April 3, 2019

Study Completion Date

April 3, 2019

Conditions

Tardive Dyskinesia (TD)

Interventions

DRUG

Valbenazine

vesicular monoamine transporter 2 (VMAT2) inhibitor

DRUG

Placebo oral capsule

non-active dosage form

Trial Locations (17)

18503

Neurocrine Clinical Site, Scranton

33012

Neurocrine Clinical Site, Hialeah

33013

Neurocrine Clinical Site, Hialeah

33018

Neurocrine Clinical Site, Hialeah

44122

Neurocrine Clinical Site, Beechwood

46804

Neurocrine Clinical Site, Fort Wayne

48105

Neurocrine Clinical Site, Ann Arbor

73112

Neurocrine Clinical Site, Oklahoma City

75062

Neurocrine Clinical Site, Irving

75115

Neurocrine Clinical Site, DeSoto

90650

Neurocrine Clinical Site, Norwalk

91206

Neurocrine Clinical Site, Glendale

92054

Neurocrine Clinical Site, Oceanside

92108

Neurocrine Clinical Site, San Bernardino

92804

Neurocrine Clinical Site, Anaheim

96817

Neurocrine Clinical Site, Honolulu

00926

Neurocrine Clinical Site, San Juan